Samantha Dale Strasser is the Chief Science Officer and co-founder of Pepper Bio. Pepper Bio is the world’s first transomics analysis company. Transomics involves analyzing a wealth of biological information from genomics all the way up to more functional data of phosphoproteomics. Pepper Bio is able to see more relevant disease insights about how to best treat disease and how to characterize potential drugs that can be used as therapeutics.
Pepper Bio has four contracts and is actively seeking partnerships with pharma. The Compass platform is Pepper Bio’s computational technology that provides the computational ability to analyze genomic, transcriptomic, proteomic, and phosphoproteomic data in a novel way through transomics to best support partners’ drug discovery questions as well as our own pipeline. Pepper Bio can work with partners early on from characterizing the disease to answer what targets are best to go after for it to staying with them through the drug discovery process to bring the power of transomics all the way through to the clinic.
Pepper Bio sees potential for shortening the timelines for drug discovery, notably around the ability to very early on select drug candidates that are most likely to be successful in the clinic. Transomics can have an impact on the massive failure rate at the very end of the drug discovery process by allowing for early identification of potential concerns of toxicity.
Listen here to learn how Pepper is changing drug discovery.
Source: Life Science Success podcast // See original post here.